ProCE Banner Activity

ExpressPoints
Managing BTK Inhibitor–Related Adverse Events and Improving Adherence

Slideset Download
Download this summary slideset with key information on managing adverse events associated with BTK inhibitors and improving adherence.

Released: September 10, 2021

Expiration: September 09, 2022

No longer available for credit.

Share

Faculty

Beth Faiman

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Amy Goodrich

Amy Goodrich, RN, MSN, CRNP-AC

Research Associate/Nurse Practitioner
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Sandra E. Kurtin

Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Janssen administered by Scientific Affairs

Pharmacyclics AbbVie

Faculty Disclosure

Primary Author

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Beth Faiman, PhD, MSN, APRN-BC, AOCN, has disclosed that she has received consulting fees from Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, and Sanofi.

Amy Goodrich, RN, MSN, CRNP-AC

Research Associate/Nurse Practitioner
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Amy Goodrich, RN, MSN, CRNP-AC, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, BioGene, Bristol-Myers Squibb, Pharmacyclics, Rigel, and Seagen.

Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

Sandra E. Kurtin, PhD, ANP-C, AOCN, has disclosed that she has received fees for consulting from AstraZeneca and Pharmacyclics.